Yuki Nishida, MD, PhD
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Graduate School of Medical Science, Saga University, Saga, JP, Ph.D. in Medical Science |
| 2007 | Kyushu University School of Medicine, Fukuoka, JP, MD |
Postgraduate Training
| 2017-2022 | Postdoctoral Fellow, Leukemia, UT MD Anderson Cancer Center, Houston, Texas |
| 2011-2012 | Chief Fellow, Medical Oncology, Kameda Medical Center, Kamogawa |
| 2009-2011 | Clinical Fellowship, Medical Oncology, Kameda Medical Center, Kamogawa |
| 2007-2009 | Clinical Residency, Internal Medicine, JCHO Kyushu Hospital, Kitakyushu |
Licenses & Certifications
| 2016 | Board Certificate for Medical Oncology, Japanese Society of Medical Oncology |
| 2013 | Board Certificate for Hematology, Japanese Society of Hematology |
Experience & Service
Faculty Academic Appointments
Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2024
Chief Physician, Kameda Medical Center, Chiba, 2013 - 2014
Honors & Awards
| 2023 | Best Poster Discussion Award (1st Place), 10th International MDM2 Workshop |
| 2023 | Best of ASH, American Society of Hematology |
| 2022 | Honorable Distinction Poster Award, Society of Hematology and Oncology |
| 2019 | Honorable Distinction Poster Award, Society of Hematologic Oncology |
| 2019 | Endowed Fellowship Award, The Kimberly Patterson Fellowship in Leukemia Research |
| 2018 - 2020 | Oversea Research Fellowship, The Japanese Society for Promoting Science |
| 2017 - 2018 | Postdoctoral Research Fellowship, The Uehara Memorial Foundation |
| 2017 | Best Paper Award, Graduate School of Medical Science, Saga University |
| 2016 | Honorable Award of Fukuoka Foundation for Sound Health Cancer Research Fund |
| 2014 | Abstract Achievement Award, American Society of Hematology |
| 2013 | Best Teacher Award in Hematology, Kameda Medical Center |
Professional Memberships
Grant & Contract Support
| Date: | 2026 - 2028 |
| Title: | Targeting Erythroid Escape in Therapy-resistant TP53 Mutant Acute Myeloid Leukemia |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | GRANT14583625/FP00029449 |
| Date: | 2026 - 2029 |
| Title: | Impact of Mitochondrial Heteroplasmy on Leukemia-Immune Microenvironment Crosstalk |
| Funding Source: | UT Austin / CPRIT |
| Role: | Key |
| ID: | FP00026244 |
| Date: | 2026 - 2031 |
| Title: | c-Myc/GSPT1 Degradation to Improve Outcome of TP53-mutated Acute Myeloid Leukemias |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00028223/GRANT14506222 |
| Date: | 2026 - 2028 |
| Title: | TP53 Mutant Acute Myeloid Leukemia Stem Cells and Erythroid Progenitors are Vulnerable to Targeted c-Myc/GSPT1 Protein Degradation |
| Funding Source: | Concern Foundation |
| Role: | PI |
| ID: | FP00028572 |
| Date: | 2026 - 2027 |
| Title: | Targeting MYC in TP53 Mutant Acute Myeloid Leukemias |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | FP00028879 |
| Date: | 2025 - 2026 |
| Title: | Combinatorial Approach of CDK9 Inhibition with MYC Protein Degradation in Therapy-resistant MYC-driven tumors |
| Funding Source: | Sellas Life |
| Role: | PI |
| ID: | RCTS 65668 |
| Date: | 2025 - 2027 |
| Title: | Targeted Protein Degradation of MYC in Relapsed/Refractory Pediatric AML |
| Funding Source: | Children’s Cancer Research Fund (CCRF) |
| Role: | Co-I |
| ID: | FP00023492 / AWD00009233 |
| Date: | 2024 - 2026 |
| Title: | c-MYC Protein Degradation in Therapy-resistant Pediatric Leukemia |
| Funding Source: | CURE Childhood Cancer, Translation to Cure |
| Role: | Co-I |
| ID: | 16766 |
| Date: | 2023 - 2024 |
| Title: | Rewiring Cancer Metabolism by Targeting MYC-driven Hematologic Malignancies |
| Funding Source: | UT Austin/MDACC Collaborative Pilot Project Grant |
| Role: | Co-PI |
| ID: | RCTS 62422 |
| Date: | 2022 - 2023 |
| Title: | Targeted Protein Degradation of MYC in Relapsed/Refractory Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | FP00018302 |
| Date: | 2022 - 2024 |
| Title: | Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21 CA267401-01 |
| Date: | 2021 - 2022 |
| Title: | Evaluating Therapeutic Potentials of c-Myc Degrader GT19715 in TP53-mutant and venetoclax/HMA resistant Acute Myeloid Leukemia and Minimal Residual Disease |
| Funding Source: | Kintor Pharma |
| Role: | Co-PI |
| ID: | RCTS 60289 |
| Date: | 2019 - 2020 |
| Title: | Therapeutic targeting of DNA-PKcs in combination with CPX-351 in acute myeloid leukemia |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
| ID: | CA186688 |
Selected Publications
Peer-Reviewed Articles
- Carter, BZ, Mak, PY, Ayoub, E, Wu, X, Ke, B, Nishida, Y, Futreal, A, Ostermann, LB, Bedoy, AD, Boettcher, S, DiNardo, C, Puzio-Kuter, A, Poyurovsky, MV, Levine, AJ, Andreeff, M. Restoring p53 wild-type conformation in TP53-Y220C–mutant acute myeloid leukemia. Blood 146(21):2574-2588, 2025. e-Pub 2025. PMID: 40608889.
- Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):729-740, 2024. e-Pub 2024. PMID: 38148395.
- Carter, BZ, Mak, PY, Tao, W, Ayoub, E, Ostermann, LB, Huang, X, Loghavi, S, Boettcher, S, Nishida, Y, Ruvolo, VR, Hughes, PE, Morrow, PK, Haferlach, T, Kornblau, SM, Muftuoglu, M, Andreeff, M. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood cancer journal 13(1), 2023. e-Pub 2023. PMID: 37088806.
- Nishida Y, Ishizawa J, Ayoub E, Heinz Montoya R, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9(48), 2023. e-Pub 2023. PMID: 38019903.
- Kurayoshi, K, Takase, Y, Ueno, M, Ohta, K, Fuse, K, Ikeda, S, Watanabe, T, Nishida, Y, Horike, Si, Hosomichi, K, Ishikawa, Y, Tadokoro, Y, Kobayashi, M, Kasahara, A, Jing, Y, Shoulkamy, MI, Meguro-Horike, M, Kojima, K, Kiyoi, H, Sugiyama, H, Nagase, H, Tajima, A, Hirao, A. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Cell Death and Disease 14(9), 2023. e-Pub 2023. PMID: 37773170.
- Carter BZ, Mak PY, Muftuoglu M, Tao W, Baozhen K, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isqandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczyemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner BP, Morgan R, Karras GI, Moll U, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood 142(12):1056-1070, 2023. e-Pub 2023. PMID: 37339579.
- Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike S, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi K, Kasahara A, Jing Y, Shoulkamy M, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Hiroki N, Tajima A, Hirao A. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Cell Death & Disease 642, 2023. e-Pub 2023.
- Carter BZ, Mak P, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo VR, Hughes P, Morrow P, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined Inhibition of BCL-2 and MCL-1 Overcomes BAX Deficiency-Mediated Resistance of TP53-mutant Acute Myeloid Leukemia to Individual BH3 Mimetics. Blood Cancer Journal 13(57), 2023. e-Pub 2023.
- Akiyama, H, Zhao, R, Nishida, Y, Ostermann, LB, Mak, PY, Ayoub, E, Piya, S, Carter, BZ, Andreeff, M, Ishizawa, J. AML-250 Mitochondrial Respiration Regulates GPX4 Inhibition-Induced Ferroptosis in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S229, 2022. e-Pub 2022. PMID: 36163797.
- Nishida, Y, Scruggs, DA, Ayoub, E, Patsilevas, T, Ruvolo, VR, Mak, PY, Carter, BZ, Boettcher, S, Maiti, A, Zhou, Q, Yang, Z, Yan, H, Ma, L, Andreeff, M. AML-147 C-MYC Targeting by Degradation. Clinical Lymphoma, Myeloma and Leukemia 22:S218, 2022. e-Pub 2022. PMID: 36163775.
- Haines E, Nishida Y, Carr MI, Montoya RH, Ostermann LB, Zhang W, Zenke FT, Blaukat A, Andreeff M, Vassilev LT. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. Sci Rep 11(1):12148, 2021. e-Pub 2021. PMID: 34108527.
- Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia 33(12):2805-2816, 2019. e-Pub 2019. PMID: 31127149.
- Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell 35(5):721-737.e9, 2019. e-Pub 2019. PMID: 31056398.
- Maeda A, Nishida Y, Weetall M, Cao L, Branstrom A, Ishizawa J, Nii T, Schober WD, Abe Y, Matsue K, Yoshimura M, Kimura S, Kojima K. Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. Oncotarget 9(47):28547-28560, 2018. e-Pub 2018. PMID: 29983879.
- Nishida Y, Kimura S, Mizobe H, Yamamichi J, Kojima K, Kawaguchi A, Fujisawa M, Matsue K. Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. Sci Rep 7(1):12885, 2017. e-Pub 2017. PMID: 29018236.
- Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J 7(2):e527, 2017. e-Pub 2017. PMID: 28211885.
- Kusaba K, Kojima K, Naito S, Taba M, Kai K, Ureshino H, Nishida Y, Kimura S. Paraneoplastic Sarcoidosis in Multiple Myeloma. Intern Med 56(15):2049-2051, 2017. e-Pub 2017. PMID: 28768979.
- Kojima K, Maeda A, Yoshimura M, Nishida Y, Kimura S. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma. Oncotarget 7(43):69625-69637, 2016. e-Pub 2016. PMID: 27626308.
- Nishida Y, Maeda A, Chachad D, Ishizawa J, Qiu YH, Kornblau SM, Kimura S, Andreeff M, Kojima K. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Sci 106(12):1705-13, 2015. e-Pub 2015. PMID: 26450753.
- Nishida Y, Matsue Y, Suehara Y, Fukumoto K, Fujisawa M, Takeuchi M, Ouchi E, Matsue K. Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. Blood Cancer J 5:e329, 2015. e-Pub 2015. PMID: 26230953.
- Sugihara H, Chihara D, Seike K, Fukumoto K, Fujisawaa M, Suehara Y, Nishida Y, Takeuchi M, Matsue K. Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment. Blood Cancer J 4:e235, 2014. e-Pub 2014. PMID: 25083819.
- Ugai T, Morisaki K, Tsuda K, Sugihara H, Nishida Y, Yamakura M, Takeuchi M, Matsue K. Cefepime-induced encephalopathy in patients with haematological malignancies: clinical features and risk factors. Scand J Infect Dis 46(4):272-9, 2014. e-Pub 2014. PMID: 24506579.
- Ugai T, Sugihara H, Nishida Y, Yamakura M, Takeuchi M, Matsue K. Capnocytophaga canimorsus sepsis following BMT in a patient with AML: possible association with functional asplenia. Bone Marrow Transplant 49(1):153-4, 2014. e-Pub 2014. PMID: 23974607.
- Yamakura M, Tsuda K, Ugai T, Sugihara H, Nisihida Y, Takeuchi M, Matsue K. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia. Acta Haematol 131(2):76-7, 2014. e-Pub 2014. PMID: 24081111.
- Nishida Y, Takeuchi K, Tsuda K, Ugai T, Sugihara H, Yamakura M, Takeuchi M, Matsue K. Acquisition of t(11;14) in a patient with chronic lymphocytic leukemia carrying both t(14;19)(q32;q13.1) and +12. Eur J Haematol 91(2):179-82, 2013. e-Pub 2013. PMID: 23581835.
- Ugai T, Tsuda K, Sugihara H, Nishida Y, Yamakura M, Takeuchi M, Matsue K. Renal Fanconi syndrome associated with monoclonal κ free light chain in a patient with Waldenström macroglobulinemia. Br J Haematol 162(1):1, 2013. e-Pub 2013. PMID: 23758066.
- Iwama K, Chihara D, Tsuda K, Ugai T, Sugihara H, Nishida Y, Yamakura M, Takeuchi M, Matsue K. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur J Haematol 90(2):134-41, 2013. e-Pub 2013. PMID: 23210517.
- Nishida Y, Iwama K, Yamakura M, Takeuchi M, Matsue K. Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib. Leuk Lymphoma 53(9):1804-6, 2012. e-Pub 2012. PMID: 22385229.
Review Articles
- Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia 35(9):2469-2481, 2021. e-Pub 2021. PMID: 34127794.
- Nishida Y, Hyakuna Y, Fujisawa K, Yamano Y, Ohshima K, Higuchi M. Composite lymphoma consisting of adult T-cell leukemia-lymphoma and diffuse large B-cell lymphoma. Rinsho Ketsueki 54(11):2062-7, 2013. e-Pub 2013. PMID: 24305540.
Other Articles
- Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):926, 2024. PMID: 38459170.
Abstracts
- Nishida Y. Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones. The 66th the American Society of Hematology Annual Meeting, 2024. e-Pub 2024.
- Munir F, Khazaei S, Calkins PH, Scruggs D, Mizuno H, Ostermann LB, Cuglievan B, Garcia MB, Chen D, Tong Y, Ren Z, Andreeff M, and Nishida Y. Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias. ASH 2023, 2023. e-Pub 2023.
- Nishida Y, Ayoub E, Scruggs D, Khazaei S, Munir F, Ostermann LB, Mak PY, Baozhen K, Carter BZ, Baran N, Maiti A, Mohanty V, Chen K, Navin N, Haferlach T, Ren Z, Tong Y, Chen D, Issa GC, Andreeff M. Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC (Best of ASH Awarded) (Oral Presentation). ASH 2023, 2023. e-Pub 2023.
- Nishida Y, Scruggs DA, Ayoub E, Ostermann LB, Patsilevas T, Ruvolo VR, Mak PY, Carter BZ, Boettcher S, Maiti A, Sasaki K, Zhou Q, Yang Z, Yan H, Ma L Andreeff M. TP53 Independent Efficacy of Novel c-MYC Degrader in MYC-driven Acute Myeloid Leukemia and Lymphoma. 85th Japanese Society of Hematology Annual Meeting, 2023. e-Pub 2023.
- Nishida Y, Ayoub E, Scruggs DA, Khazaei S, Munir F, Ostermann LB, Mak PY, Ke B, Carter BZ, Baran N, Maiti A, Mohanty V, Chen K, Navin N, Haferlach T, Ren Z, Tong Y, Chen D, Issa GC, Andreeff M. TP53 Mutant Acute Myeloid Leukemias comprise Stem-like Cell Enriched Cellular Hierarchy and are Vulnerable to Targeted Protein Degradation of c-MYC (Best Poster Discussion Award). 10th MDM2 Workshop, 2023. e-Pub 2023.
- Carter BZ, Mak PY, Ke B, Nishida Y, Boettcher S, Bedoy A, Ostermann LB, DiNardo CD, Puzio-Kuter A, Levine A, Andreeff M. Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2. ASH 2023, 2023. e-Pub 2023.
- Ayoub E, Li L, Muftuoglu M, Nishida Y, Mohanty V, Leighton JS, Patsilevas T, Basyal M, Bedoy A, Haferlach T, Takahashi K, Chen K, Navin N, Issa GC, Andreeff M. Single-Cell Genomics and Proteomics Reveals Venetoclax-Resistant Monocytic Differentiation of TP53 LOH Clones in TP53 Mutant AML. ASH 2023, 2023. e-Pub 2023.
- Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo VR, Mak PY, Carter BZ, Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in Acute Myeloid Leukemia and Lymphomas. Bloood 22(S2):S218, 2022. e-Pub 2022.
- Akiyama H, Zhao R, Nishida Y, Baran N, Li Z, Ostermann LB, Mak PY, Ayoub E, Piya S, Carter BZ, Andreeff M, Ishizawa J. Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia. Blood 140(S1):8785-8786, 2022. e-Pub 2022.
- Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo VR, Mak PY, Carter BZ, Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in Acute Myeloid Leukemia and Lymphomas. (Oral Presentation). Blood 140(S1):483-484, 2022. e-Pub 2022.
- Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann LB, Heinz Montoya R, Muftuoglu M, Ruvolo VR, Mak PY, Tao W, Carter BZ, Scruggs DA, Kojima K, Daver NG, Lesegretain A, Seki T, Shacham S, Konopleva M, Andreeff M. The Triple Inhibition of MDM2, XPO1 and BCL-2 Profoundly Induce Cell Kill in Ven/HMA Resistant AML (Oral Presentation). The 84th Japanese Society of Hematology Annual Meeting, 2022. e-Pub 2022.
- Ayoub E, Marupudi A, Nishida Y, Heinz Montoya R, Mohanty V, Walter W, Bray MR, Patsilevas T, Boettcher S, Issa GC, Chen K, Haferlach T, Borthakur G, Andreeff M. Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage. Blood 140(S1):5941-5943, 2022. e-Pub 2022.
- Carter BZ, Mak PY, Tao W, Ostermann LB, Nishida Y, Pemmaraju N, Boettcher S, Shpall EJ, Chiosis G, Karras G, Wallner B, Morgan RA, Andreeff M. Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML. Blood 140(S1):5930-5931, 2022. e-Pub 2022.
- Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann LB, Heinz Montoya R, Muftuoglu M, Ruvolo VR, Mak PY, Tao W, Carter BZ, Kojima K, Daver N, Lesegretain A, Seki T, Shacham S, Konopleva M, Andreeff M. Enhanced p53 Activation by Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML. Blood 138(S1):505-506, 2021. e-Pub 2021.
- Jia Y, Zhang Q, Weng C, Ramage CL, Nishida Y, Chao M, Maute RL, Herbrich S, Zhang W, Andreeff M, Daver N, Konopleva M. Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models. Blood 138(S1), 2021. e-Pub 2021.
- Carter BZ, Tao W, Ostermann LB, Mu-Mosley H, Mak PY, Boettcher S, Nishida Y, Tao R, Lang E, Zhai Y, Yang D, Andreeff M. Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells. Blood 138(S1), 2021. e-Pub 2021.
- Carter BZ, Mak PY, Tao W, Ostermann LB, Boettcher S, Nishida Y, Ayoub E, Ruvolo V, Jabbour EJ, Hughes P, Morrow PK, Andreeff M. Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics. Blood 138(S1), 2021. e-Pub 2021.
- Akiyama H, Zhao R, Rahhal A, Nishida Y, Ayoub E, Ostermann LB, Andreeff M, Ishizawa J. Therapeutic Targeting of Ferroptosis Pathway in Combination with Mitochondrial Oxidative Stress Induction in Acute Myeloid Leukemia. Blood 138(S1), 2021. e-Pub 2021.
- Nishida Y, Ishizawa J, Ayoub E, Heinz Montoya R, Ruvolo V, Kojima K, Daver N, Lesegretain A, Shacham S, Andreeff M. Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias. Blood 136(S1):23-24, 2020. e-Pub 2020.
- Nishida Y, Heinz Montoya R, Morita K, Tanaka T, Wang F, Takahashi K, Ishizawa J, Kumar P, Patel P, Dos Santos CE, DiNardo CD, Andreeff M. Clonal Expansion of Mutant p53 Clones by MDM2 Inhibition in Acute Myeloid Leukemias. Blood 136(S1):27-28, 2020. e-Pub 2020.
- Carter BZ, PhD, Mak PY, Tao W, Ruvolo V, Zhang X, Nishida Y, Kornblau SM, Hughes P, Chen X, Morrow PK, l Andreeff M. Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML. Blood 136(S1), 2020. e-Pub 2020.
- Chang KH, Alaniz Z, Nishida Y, Dos Santos CE, Slosberg E, Daver N, Andreeff M. Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells. Blood 136(S1), 2020. e-Pub 2020.
- Muftuoglu M, Mak PY, Ruvolo V, Nishida Y, Ruvolo PP, Carter BZ, Andreeff M. High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML. Blood 136(S1), 2020. e-Pub 2020.
- Muftuoglu M, Ruvolo V, Nishida Y, Mak PY, Ruvolo P, Carter BZ, Andreeff M. Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns. Blood 134(S1), 2019. e-Pub 2019.
- Nishida Y, Ishizawa J, Ruvolo V, Kojima K, Montoya RH, Daver NG, Lesegretain A, Shachem S, Andreeff M. Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc. Blood 134(S1), 2019. e-Pub 2019.
- Nishida Y, Ishizawa J, Ruvolo V, Wang F, Takahashi K, Mak PY, Carter BZ, Andreeff M. TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia. Blood 134(S1):1251, 2019. e-Pub 2019.
- Nishida Y, Ishizawa J, Ruvolo V, Andreeff M. TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors. Blood 132(S1):2629, 2018. e-Pub 2018.
Letters to the Editor
- Akiyama H, Nishida Y, Chang KY, Bedoy AD, Muftuoglu M, Ma W, Basyal M, Hirschi Z, Honma D, Tsutsumi S, Wang J, Huang X, Rampal RK, Oluwole OO, Bixby DL, Daver NG, Andreeff M. Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia. Blood Cancer J 15: 76, 2025.
Patient Reviews
CV information above last modified July 22, 2026